New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 9, 2012
10:31 EDTHLF, WTW, VNET, JNJ, LPNT, VHS, NLS, JPM, DKSOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Herbalife (HLF) initiated with an Overweight at Barclays...Weight Watchers (WTW) initiated with an Overweight at Barclays...21Vianet Group (VNET) initiated with a Buy at Stifel Nicolaus...Johnson & Johnson (JNJ) initiated with a Hold at Jefferies...LifePoint Hospitals (LPNT) initiated with a Buy at Cantor...Vanguard Health (VHS) initiated with a Buy at Cantor...Nautilus (NLS) initiated with an Outperform at Northland Securities...JPMorgan (JPM) initiated with a Buy at Guggenheim...Dick's (DKS) Sporting initiated with a Buy at Argus.
News For HLF;WTW;VNET;JNJ;LPNT;VHS;NLS;JPM;DKS From The Last 14 Days
Check below for free stories on HLF;WTW;VNET;JNJ;LPNT;VHS;NLS;JPM;DKS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>
July 15, 2014
08:25 EDTJNJJohnson & Johnson says innovation sustaining long-term growth
Says MD&D progressing well towards 30 major filings by 2017. In Pharmaceuticals, sees 10 new products and 25 significant line extensions planned by 2017. Sees ~4.5% CAGR expected for WW prescription drug sales through 2017, despite potential headwinds. Comments from slides that will be presented on the Q2 earnings conference call.
07:49 EDTJNJJohnson & Johnson reports Q2 Worldwide Pharmaceutical sales of $8.5B
Subscribe for More Information
07:48 EDTJNJJohnson & Johnson raises FY14 EPS to $5.85-$5.92 from $5.75-$5.85
Subscribe for More Information
07:47 EDTJNJJohnson & Johnson reports Q2 Domestic sales up 14.9% to $9.13B
Subscribe for More Information
07:46 EDTJNJJohnson & Johnson reports Q2 EPS excluding items $1.66, consensus $1.55
Subscribe for More Information
07:23 EDTJPMFortune to hold a conference
Subscribe for More Information
07:08 EDTJPMJPMorgan CEO says saw encouraging signs toward end of Q2
Subscribe for More Information
07:06 EDTJPMJPMorgan reports Q2 Basel III Common Equity Tier 1 ratio 9.8%
Reports Common Equity Tier 1 of $161B, or ratio of 9.8%. Reports Firm Supplementary Leverage Ratio of 5.4%. Reports "core loans" up 8% compared with the prior year. Consumer & Community Banking: average Consumer & Business Banking deposits up 9%; credit card sales volume up 12%; record client investment assets up 19%; record Business Banking loan originations up 46% Corporate & Investment Bank: maintained #1 ranking for Global Investment Banking fees with 8.2% wallet share YTD; assets under custody up 14%. Commercial Banking: period-end loan balances up 9%, driven by 14% growth in Commercial Real Estate; gross investment banking revenue with Commercial Banking clients up 25%. Asset Management: twenty-first consecutive quarter of positive net long-term client flows; record client assets up 15%; record loan balances up 17%.
07:05 EDTJPMJPMorgan reports headcount down 8,871 to 245,192
Subscribe for More Information
07:04 EDTJPMJPMorgan reports Q2 provision for credit losses $692M
Subscribe for More Information
07:02 EDTJPMJPMorgan says Q2 results include $500M after-tax, or 13c, legal expense
Subscribe for More Information
07:01 EDTJPMJPMorgan reports Q2 adjusted EPS $1.46, consensus $1.29
Subscribe for More Information
06:19 EDTJPMJPMorgan reports June net charge losses 2.84% vs. 3.05% last month
Subscribe for More Information
July 14, 2014
15:24 EDTJNJ, JPMNotable companies reporting before tomorrow's open
Subscribe for More Information
15:19 EDTJNJ Johnson & Johnson July 105 straddle priced for 1.6% move into Q2
14:40 EDTJPMJPMorgan July 56.5 straddle priced for 2.2% move into Q2
Subscribe for More Information
14:27 EDTJNJEarnings Preview: J&J pharmaceutical sales expected to drive Q2
Johnson & Johnson (JNJ) is scheduled to report second quarter earnings before the market open on Tuesday, July 15, with a conference call scheduled for 8:30 am ET. Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. EXPECTATIONS: Analysts are looking for earnings per share of $1.55 on revenue of $18.94B, according to First Call. The consensus range for EPS is $1.45-$1.61 on revenue of $18.55B-$19.30B. LAST QUARTER: Johnson & Johnson reported first quarter EPS of $1.54 against estimates of $1.48 on revenue of $18.1B against estimates of $18B. The drug maker raised its fiscal year EPS view to $5.80-$5.90 against a consensus estimate of $5.83. J&J noted a 3.2% decrease in worldwide consumer sales in Q1 but saw a 10.8% increase in worldwide pharmaceutical sales. Primary contributors to operational sales growth in Q1 pharmaceutical sales were Stelara, Invega, Sustenna/Xeplion, Prezista, Velcade and sales of new products. Pharmaceutical sales results were negatively impacted by loss of exclusivity for Aciphex, a proton pump inhibitor for gastrointestinal disorders and Concerta for the treatment of attention deficit hyperactivity disorder. STREET RESEARCH: On July 14, RBC Capital raised its Q2 estimates for Johnson & Johnson to reflect the firm's outlook for higher pharmaceutical sales by the company. The firm raised its price target on the shares to $110 from $106 and kept an Outperform rating on the stock. PRICE ACTION: Shares of Johnson & Johnson are up approximately 8.5% since its last earnings report, and are trading near flat in afternoon trading.
12:24 EDTJNJJohnson & Johnson technical notes before earnings
The company is scheduled to report before market open on July 15th. The shares in the prior three months have risen by more than 8%, anticipating positive news for the current and forthcoming quarters. At the current price of $105.39, the only remaining established resistance on the daily chart is at the life high of $106.74. If the news and guidance is better than expected, a run to $110, or $115 at an extreme, would be possible. If the news fails to meet expectations or guidance is weak, support would be at $102.70, the 50-day moving average. A break below this uptrend support proxy would be a sell signal in many technical trading systems and would break an uptrend in place since early March of this year. On a sliding scale of increasingly weaker news, supports would next be at $99.96, and then at $96.87.
08:30 EDTJNJJohnson & Johnson should be bought on any weakness, says RBC Capital
Subscribe for More Information
08:01 EDTJPMJP Morgan July volatility increases into Q2 and outlook
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use